Apellis Pharmaceuticals Inc (APLS) - Total Liabilities

Latest as of March 2026: $667.61 Million USD

Based on the latest financial reports, Apellis Pharmaceuticals Inc (APLS) has total liabilities worth $667.61 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore APLS net assets growth trend to track the company's year-over-year net asset growth rate.

Apellis Pharmaceuticals Inc - Total Liabilities Trend (2013–2025)

This chart illustrates how Apellis Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Apellis Pharmaceuticals Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Apellis Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Apellis Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Actron Technology TWO:8255	Taiwan	NT$5.77 Billion
Sinosun Tech SHE:300333	China	CN¥13.94 Million
Gruvaktiebolaget Viscaria ST:VISC	Sweden	Skr1.16 Billion
Banestes S.A - Banco do Estado do Espírito Santo SA:BEES3	Brazil	R$36.68 Billion
Yuanbao Inc. American Depositary Shares NASDAQ:YB	USA	$1.71 Billion
Dingli Communications Corp Ltd SHE:300050	China	CN¥176.85 Million
AdvanSix Inc NYSE:ASIX	USA	$870.12 Million
Fenix Outdoor International AG ST:FOI-B	Sweden	Skr340.00 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Apellis Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Apellis Pharmaceuticals Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.63	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.61	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.62	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Apellis Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Apellis Pharmaceuticals Inc (2013–2025)

The table below shows the annual total liabilities of Apellis Pharmaceuticals Inc from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	$705.11 Million	+7.40%
2024-12-31	$656.51 Million	+10.49%
2023-12-31	$594.21 Million	+0.65%
2022-12-31	$590.35 Million	-13.58%
2021-12-31	$683.10 Million	-9.64%
2020-12-31	$756.01 Million	+112.95%
2019-12-31	$355.02 Million	+734.13%
2018-12-31	$42.56 Million	+28.24%
2017-12-31	$33.19 Million	+812.04%
2016-12-31	$3.64 Million	+13.71%
2015-12-31	$3.20 Million	+195.89%
2014-12-31	$1.08 Million	+59.76%
2013-12-31	$676.96K	--

About Apellis Pharmaceuticals Inc

NASDAQ:APLS USA Biotechnology

Market Cap

$435.53 Million

Market Cap Rank

#12753 Global

#3140 in USA

Share Price

$3.40

Change (1 day)

+8.67%

52-Week Range

$3.05 - $41.12

All Time High

$93.31